[HTML][HTML] Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant
…, K Molapo, A Moultrie, S Oelofse, F Patel… - … England Journal of …, 2021 - Mass Medical Soc
Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an …
…, T Moyo-Gwete, AJ Nana, A Nzimande, F Patel… - The Lancet …, 2021 - thelancet.com
Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …
Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa
…, S McKenzie, K Molapo, A Moultrie, S Oelofse, F Patel… - MedRxiv, 2021 - medrxiv.org
Background Assessing safety and efficacy of Covid-19 vaccines in different populations is
essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern …
essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern …
[HTML][HTML] Effectiveness of the Ad26. COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B …
…, P Mohlala, A Ward, G Meintjes, D Urbach, F Patel… - The Lancet, 2022 - thelancet.com
Background We aimed to assess the effectiveness of a single dose of the Ad26.COV2.S
vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the …
vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the …
[HTML][HTML] Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA. 1 and BA. 4 6 months after …
…, T Motlou, N Mzindle, S Oelofse, F Patel… - The Lancet Infectious …, 2023 - thelancet.com
Background COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate
of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before …
of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before …
[HTML][HTML] Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children
…, B Da Costa Dias, S Loubser, R Strehlau, F Patel… - PloS one, 2018 - journals.plos.org
Background The latent viral reservoir is the major obstacle to achieving HIV remission and
necessitates life-long antiretroviral therapy (ART) for HIV-infected individuals. Studies in …
necessitates life-long antiretroviral therapy (ART) for HIV-infected individuals. Studies in …
[HTML][HTML] Early antiretroviral treatment of infants to attain HIV remission
Background Studies in adults and children suggested that starting antiretroviral therapy (ART)
soon after infection positively influences early events in HIV infection raising the possibility …
soon after infection positively influences early events in HIV infection raising the possibility …
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy
…, S Shiau, R Strehlau, L Martens, F Patel… - Archives of disease in …, 2013 - adc.bmj.com
Background Few studies have assessed metabolic and body composition alterations in
perinatally HIV-infected African children on antiretroviral therapy (ART). We compared metabolic …
perinatally HIV-infected African children on antiretroviral therapy (ART). We compared metabolic …
[HTML][HTML] Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an …
…, C Khamrong, L Aurpibul, L Fairlie, F Patel… - The Lancet …, 2022 - thelancet.com
Background Safe and potent antiretroviral medications in child-friendly formulations are
needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible …
needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible …
Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human …
S Shiau, S Arpadi, R Strehlau, L Martens, F Patel… - The Journal of …, 2013 - Elsevier
OBJECTIVE: To describe the effects of age at antiretroviral therapy (ART) initiation on growth
outcomes among children infected with HIV followed for 48 months after treatment initiation. …
outcomes among children infected with HIV followed for 48 months after treatment initiation. …